Pharmafile Logo
Pharmafocus logo
Advanced Search

WHO report reveals antibiotic use by country

November 14, 2018
Research and Development

Britain uses more than twice as many antibiotics as the Netherlands, according to a new report published by the World …

News
samsung_bioepis

Samsung BioLogics delisted over accounting violations

November 14, 2018
Research and Development Business, Samsung, Samsung BioLogics, accounting, south korea

South Korean firm Samsung BioLogics has been delisted from the South Korean stock exchange. The decision has come after the …

News
novartis_window

Novartis’ Entresto tops enalapril in stabilised heart failure patients

November 13, 2018
Manufacturing and Production, Research and Development Entresto, Novartis, cardiovascular, enalapril, heart failure, pharma

Novartis has declared new findings for Entresto (sacubitril/valsartan) at the American Heart Association’s (AHA) scientific sessions, showing that the drug proved …

News
michael_boyd

Gilead appoint Pfizer and AbbVie veteran as VP of governmental affairs

November 13, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

American antiviral drug specialist Gilead have appointed Pfizer and AbbVie veteran Michael Boyd as VP of government affairs and policy …

Appointment

Cases of measles nearly quadruple since last year in UK

November 13, 2018
Manufacturing and Production MMR, Public Health England, UK, health, measles

Public Health England is urging the public to ensure that they have received two doses of the MMR vaccine after …

News
acute_lymphoblastic_leukaemia_smear

Azacitidine and nivolumab combo proves successful in phase II trial

November 13, 2018
Manufacturing and Production Cancer, leukaemia, opdivo, pharma, texas

A combination of chemotherapy drug azacitidine and nivolumab (Bristol-Myers Squibb’s Opdivo) has proven effective in treating patients with relapsed or …

News
shutterstock_273326141

AstraZeneca sells off paediatric lung infection drug to Sobi for $1.5bn

November 13, 2018
Manufacturing and Production, Sales and Marketing AstraZeneca, Synagis, espiratory syncytial virus, pharma, sobi

AstraZeneca has jettisoned another non-essential asset with the sale of Synagis (palivizumab), a preventative treatment for infections relating to respiratory …

News
samsung

Samsung Biologics shares fall by 20% after Korean investigation

November 13, 2018
Manufacturing and Production Shares, accounting, pharma, smasung biologics, stockmarket

Shares in Korean firm Samsung BioLogics plummeted this week, falling by as much as 20% on Monday, after the South …

News
msd

MSD’s Keytruda chalks up FDA approval in liver cancer

November 12, 2018
Sales and Marketing Cancer, FDA, US, hepatocellular carcinoma, keytruda, pharma

MSD’s blockbuster immunotherapy Keytruda has secured another FDA approval, this time for the treatment of hepatocellular carcinoma (HCC) in patients …

News

Working Life: Philippe Bastide, Head of Biosimilars, Mundipharma

November 12, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, Mundipharma, Philippe Bastide, biosimilars, leukaemia

“Don’t conform to what people want – take risks. The people who make a big difference are the ones who …

Feature
5204602349_c87b204860_z

FDA commissioner Scott Gottlieb says that more rigorous approval process would be unique to opioids

November 12, 2018
Sales and Marketing FDA, Gottlieb, opioid crisis, opioids

Food and Drug Administration (FDA) commissioner Scott Gottlieb has said that if a more rigorous approval process is introduced for …

News
astrazeneca_building_white

AZ’s Farxiga shows strength in largest ever SGLT2 inhibitor cardiovascular outcomes study

November 12, 2018
Research and Development, Sales and Marketing AstraZeneca, cardiovascular, farxiga, pharma

AstraZeneca has revealed new data for its sodium-glucose co-transporter 2 (SGLT2) inhibitor Farxiga (dapagliflozin) at the American Heart Association (AHA) …

News
28246711066_52e38bc591_z

No-deal Brexit preparations are a waste of time and money, according to Welsh industry representatives

November 12, 2018
Sales and Marketing ABPI, brexit, no-deal, pharma, stockpiling

The UK government’s request that pharmaceutical companies stockpile an additional six weeks’ worth of medicine, in preparation for a no-deal …

News
congo_ebola

Hundreds die in worst Ebola outbreak in Congo’s history

November 12, 2018
Sales and Marketing

Hundreds have died in a recent outbreak of Ebola in the Democratic Republic of Congo (DRC), in what has been …

News
dave_tudor

GSK veteran Dave Tudor joins MMIC in Scotland

November 9, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing GSK, Scotland, dave tudor, life sciences, manufacturing

GlaxoSmithKline veteran, Dave Tudor, is set to take on the role of Managing Director of the Medicines Manufacturing Innovation Centre …

Appointment
eisa0001

Eisai’s Lenvima wins over NICE in liver cancer in just three months

November 9, 2018
Medical Communications, Sales and Marketing Cancer, Eisai, Lenvima, Levantinib, NHS, NICE, UK, liver cancer, pharma

Eisai has revealed that its multireceptor Tyrosine Kinase Inhibitor Lenvima (lenvatinib) has been recommended by NICE, meaning it can now …

News
top_10_image

Top Ten most popular articles on Pharmafile.com this week!

November 9, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Celgene, GSK, Novo Nordisk, politics, popular, top 10, vaccines

The biggest news this week came from Israeli biotech Zion Medical after it was announced that HIV drug Gammora was …

News
nice_new_london_office_internal_2_8

NICE fail to recommend AstraZeneca’s cancer drug Olaparib on cost effectiveness basis

November 9, 2018
Medical Communications, Sales and Marketing AstraZeneca, NHS, NICE, UK, olaparib, pharma

Britain’s cost effectiveness body the National Institute of Health and Care Excellence (NICE) has chosen not to recommend AstraZeneca’s Olaparib …

News

NHS diabetes prescriptions top £1 billion a year

November 9, 2018
Medical Communications, Sales and Marketing Health Education England, NHS, UK, diabetes, pharma

The NHS in England is now spending over £1billion a year on diabetes prescriptions, almost doubling in the last decade, …

News
opioid_pills

Alabama’s biggest insurer will no longer cover OxyContin prescriptions

November 9, 2018
Medical Communications Alabama, Blue Cross and Blue Shield, OxyContin, insurance, opioids

The state of Alabama’s biggest insurer Blue Cross and Blue Shield will no long cover opioid painkiller OxyContin. The decision …

News
The Gateway to Local Adoption Series

Latest content

Could targeting the molecular causes of infertility finally transform IVF success rates?

January 29, 2026

Digital mental health technologies – a valuable tool in supporting people with depression and anxiety

January 29, 2026

Barts Health NHS Trust collaborates with H.I.G. Realty on healthcare innovation building

January 29, 2026

Rentschler Biopharma appoints Detra Glinatsis as Head of Business Development US

January 29, 2026

Five Facts about spinal muscular atrophy

January 28, 2026